Navigation Links
Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
Date:7/25/2012

FORT WORTH, Texas, July 25, 2012 /PRNewswire/ -- Healthpoint Biotherapeutics today announced that the results of a 24-week open-label follow-up to the HP802-247 Phase 2b trial will be presented by Robert Kirsner, MD, PhD, on Friday, July 27, 2012, from 3:55-4:15 pm, during the American College of Wound Healing and Tissue Repair held at the Swissotel in Chicago. HP802-247 is an allogeneic living cell bioformulation containing keratinocytes and fibroblasts currently being investigated for the treatment of venous leg ulcers.

Venous leg ulcers affect approximately 2.5 million Americans and are associated with impaired circulation most commonly resulting from damaged veins and/or valves. They typically appear as an open lesion, or ulcer, on the lower extremities, are very slow to heal and often reoccur due to the chronic nature of the underlying disease process.

The Phase 2b trial was designed to determine the potential effectiveness of two cell concentrations and two dosing frequencies of HP802-247, when combined with standard care, compared to control plus standard care, in healing venous leg ulcers over a 12-week treatment period. The study was a randomized, double blind, dose-finding study involving 228 subjects enrolled across 35 investigational centers in the United States. Overall, HP802-247 achieved statistical significance, as compared with control plus standard care, in both the primary and secondary endpoints. HP802-247 was generally well tolerated in the study with the most frequently reported adverse events being skin ulcers, cellulitis, wound infection and skin irritation.  The safety profile of the active groups was similar to the vehicle control.

The 24-week open-label extension of this Phase 2b trial was designed to evaluate the status of the target wound (e.g., open, re-opened or healed), as well as the status of the periwound area following the 12-week treatment period. HP802-247 was not administered to patients durin
'/>"/>

SOURCE Healthpoint Biotherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
2. Robert Farrell Joins Bionovos Board of Directors
3. Engineer Robert J. Wood to receive NSFs Alan T. Waterman Award
4. Fortis Vice President of Nursing Robert Anders Named Academy of Nursing Education Fellow by National League for Nursing
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
6. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
7. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
10. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
11. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... MAR, Calif. , Sept. 30, 2014 ... for women,s health announces its receipt of a patent ... FemmyCycle menstrual cup has also received FDA clearance in ... Canada, and the CE in Europe. This patent is related ... conjunction with this issuance, the company is releasing FemmyCycle ...
(Date:9/30/2014)... September 30, 2014 SoundConnect, ... collaboration company is dedicated to supporting business communication ... Julie Power, a carrier services ... collaboration solutions stays connected and productive at all ... increased movement of businesses to cloud communications services. ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Back in the ... 500 square feet. per employee, which included space for circulation ... then.” says Jeff Howell, partner at Nidea Corporate Real ... in Toronto. “By the year 2000, however, 250 square ... seeing that number come down to 175 to 225 square ...
(Date:9/29/2014)... , Sept. 29, 2014  Ten of ... fields of cartilage repair, regeneration, allograft reconstruction and ... around the world gathered to discuss the future ... Institute of Regenerative Medicine symposium, Cartilage Regeneration: ... Topics included Orthopedic Biosurgery, Minced Juvenile Allograft, and ...
Breaking Biology Technology:The FemmyCycle 2SoundConnect Expands Carrier Services Division 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3
... LOUIS, Aug. 27 Missouri Coalition for,Lifesaving Cures ... far-,reaching initiative petition filed last week by opponents ... worded and scientifically unsound that it,would exclude Missourians ... syndromes from its definition of "human." In ...
... Drug Royalty LP 2 (DRC) announced,today the ... worldwide,royalty interest in PEG-INTRON for $92.5M. DRC will ... certain royalty recognition levels be met.,PEG-INTRON (peginterferon alpha-2b), ... is marketed worldwide by Schering-Plough Corporation (SGP). ...
... 27 NovaQuest has,made a strategic investment ... specializing in respiratory,disorders. The investment was part ... million) in the Montreal-based company. Last ... partnering group,of Quintiles Transnational, helps TOPIGEN accelerate ...
Cached Biology Technology:New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human 2Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN) 2NovaQuest Advances 'Virtual Development' Model With Strategic Investment in TOPIGEN Pharmaceuticals 2
(Date:9/30/2014)... (LMU) in Munich report that a new class ... to chemotherapeutic drugs. They have also pinpointed the ... for anti-tumor agents. , Researchers led by ... of the Technische Universitt Mnchen have identified a ... weapon in the fight against malignant tumors. The ...
(Date:9/30/2014)... a suite of perilous threats in today,s ocean. ... climate change, fragile coral ecosystems are disappearing at ... some species of corals surrounding the island of ... in their tropical environment: coral guard-crabs. New research ... Marine Station scientist Seabird McKeon and the museum,s ...
(Date:9/29/2014)... DC September 29, 2014 -- Plants have ... bacteria help the pants extract nutrients and defend ... pathogens from contaminating fruits and vegetables. Now, scientist ... bacteria inside of seeds; thus ensuring that sprouting ... from the University of Notre Dame, presented their ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Smithsonian scientists discover coral's best defender against an army of sea stars 2Plants prepackage beneficial microbes in their seeds 2
... of their woody material, could be the key to a ... who add that the approach could also help turn agricultural ... component of woody plant material, is woven in with cellulose ... of wind and microbial attack. However, this protective barrier or ...
... NEW YORK, Dec. 22, 2008 NYU Langone Medical Center ... La Jolla, Calif., have discovered an unexpected cause for the ... of the central nervous system, according to a study published ... new way of thinking about how the human immune system ...
... for humans, Plasmodium falciparum , has been linked ... fairly isolated on the malarial family treeuntil now. A ... Genomics at the American Museum of Natural History reveals ... close evolutionary relationship with P. falciparum and ...
Cached Biology News:Modified plants may yield more biofuel 2Peering inside the skull of a mouse to solve meningitis mystery 2Peering inside the skull of a mouse to solve meningitis mystery 3African thicket rat malaria linked to virulent human form 2
...
... reagent; Ideal for clarifying many items ... nucleic acids, & proteoglycans; Contains no ... downstream processing; Utilizes a reagent that ... as a suspension in saline; Simple ...
A simple, sensitive and reliable method for determining free sulfhydryl content in peptides, protein...
... Tecans open platform for clinical diagnostic applications, ... performance in the clinical diagnostic and blood ... barcode reading and sample traceability as standard ... complies with the IVD-Directive* established in the ...
Biology Products: